Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Germing

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Blood|November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
Leukemia|December 16, 2015
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)E Schuler, A Giagounidis, D Haase, et al.
Leukemia|November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patientsU Platzbecker, H K Al-Ali, N Gattermann, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Leukemia|January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classificationK Nachtkamp, C Strupp, M Vukelja, et al.
Leukemia|April 18, 2006
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrowW Ingram, N C Lea, J Cervera, et al.
Leukemia|May 3, 2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)M Mossner, J-C Jann, D Nowak, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Blood|November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
Leukemia|December 16, 2015
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)E Schuler, A Giagounidis, D Haase, et al.
Leukemia|November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patientsU Platzbecker, H K Al-Ali, N Gattermann, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Leukemia|January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classificationK Nachtkamp, C Strupp, M Vukelja, et al.
Leukemia|April 18, 2006
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrowW Ingram, N C Lea, J Cervera, et al.
Leukemia|May 3, 2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)M Mossner, J-C Jann, D Nowak, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Pageof 13